Page last updated: 2024-11-12

cgp 57380

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11644425
CHEMBL ID1240885
CHEBI ID92749
SCHEMBL ID16714452
SCHEMBL ID987991
MeSH IDM0440593

Synonyms (52)

Synonym
cgp57380
cgp-57380
cgp 57380
HMS3269P13
BRD-K42500029-001-01-9
cgp 57380, >=98% (hplc)
mnk1 inhibitor
NCGC00162380-01
NCGC00162380-02
NCGC00162380-03
bdbm50130693
522629-08-9
HMS3229K20
nsc741567
nsc-741567
n-(4-fluorophenyl)-3h-pyrazolo[3,4-d]pyrimidine-3,4-diamine
chembl1240885 ,
bdbm50298223
HMS3263L14
n3-(4-fluorophenyl)-1h-pyrazolo[3,4-d]pyrimidine-3,4-diamine
LP01256
S7421
3-n-(4-fluorophenyl)-2h-pyrazolo[3,4-d]pyrimidine-3,4-diamine
gtpl6010
CCG-206868
tox21_501256
NCGC00261941-01
SCHEMBL16714452
SCHEMBL987991
n3-(4-fluorophenyl)-1h-pyrazolo-[3,4-d]pyrimidine-3,4-diamine
AKOS024457265
HMS3648M14
DTXSID50469941
CHEBI:92749
HMS3653G22
NCGC00162380-06
nsc 741567
SW219758-1
mnk1 inhibitor - cas 522629-08-9
HMS3677D16
Q27087429
SR-02000000869-2
sr-02000000869
BCP27993
cgp57380;cgp-57380
HMS3413D16
HMS3673K05
SDCCGSBI-0086774.P002
NCGC00162380-09
C75450
AS-56092
A902707

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrazolopyrimidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.39810.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID493107
GLS proteinHomo sapiens (human)Potency10.00000.35487.935539.8107AID624146
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency21.13170.001530.607315,848.9004AID1224821; AID1224823
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency5.21190.00378.618923.2809AID2668
Ataxin-2Homo sapiens (human)Potency25.11890.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serine/threonine-protein kinase Sgk1Homo sapiens (human)IC50 (µMol)2.70000.00680.86653.5700AID435213; AID509610
Dual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)IC50 (µMol)3.20000.01140.78593.2000AID435335
Cyclin-T1Homo sapiens (human)Ki10.00000.00300.27680.7900AID1255410
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)1.60000.00011.774010.0000AID1399572
Proto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)IC50 (µMol)2.50000.00040.62452.5000AID435949
Eukaryotic translation initiation factor 4EHomo sapiens (human)IC50 (µMol)3.00003.00003.00003.0000AID1846620
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)1.60000.00002.015110.0000AID1399572
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)IC50 (µMol)5.00000.10002.67828.0000AID606664
Cyclin-A2Homo sapiens (human)Ki10.00000.00100.70075.0000AID1255409
Cyclin-dependent kinase 2Homo sapiens (human)Ki10.00000.00050.64275.0000AID1255409
Casein kinase I isoform deltaHomo sapiens (human)IC50 (µMol)0.51000.00401.127210.0000AID435450
Cyclin-dependent kinase 9Homo sapiens (human)Ki10.00000.00300.24820.7900AID1255410
Cyclin-A1Homo sapiens (human)Ki10.00000.00400.14800.2500AID1255409
Serine/threonine-protein kinase BRSK2Homo sapiens (human)IC50 (µMol)1.10000.00230.25911.1000AID436061
Aurora kinase BHomo sapiens (human)IC50 (µMol)2.50000.00030.96349.8000AID435206
MAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)IC50 (µMol)1.21820.00701.11693.0100AID1255414; AID1399566; AID1534877; AID1544516; AID1769037; AID1846619; AID1846621; AID1881762; AID1907986; AID435837; AID509582
MAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)Ki1.01001.01001.01001.0100AID1201660; AID1255414
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)IC50 (µMol)2.06000.00700.95946.2700AID1255413; AID1399567; AID1399572; AID1534878; AID1769038; AID1846622; AID1881763; AID1907987; AID435576; AID509584
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)Ki0.61000.34000.61000.8800AID1201661; AID1255408
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (231)

Processvia Protein(s)Taxonomy
regulation of cell growthSerine/threonine-protein kinase Sgk1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Sgk1Homo sapiens (human)
sodium ion transportSerine/threonine-protein kinase Sgk1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase Sgk1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Sgk1Homo sapiens (human)
long-term memorySerine/threonine-protein kinase Sgk1Homo sapiens (human)
regulation of blood pressureSerine/threonine-protein kinase Sgk1Homo sapiens (human)
regulation of cell migrationSerine/threonine-protein kinase Sgk1Homo sapiens (human)
positive regulation of transporter activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase Sgk1Homo sapiens (human)
regulation of apoptotic processSerine/threonine-protein kinase Sgk1Homo sapiens (human)
regulation of catalytic activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
regulation of gastric acid secretionSerine/threonine-protein kinase Sgk1Homo sapiens (human)
renal sodium ion absorptionSerine/threonine-protein kinase Sgk1Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase Sgk1Homo sapiens (human)
cellular response to aldosteroneSerine/threonine-protein kinase Sgk1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Sgk1Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase Sgk1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase Sgk1Homo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
erythrocyte differentiationDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
nuclear speck organizationDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
stress granule disassemblyDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
negative regulation of apoptotic processDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
cell divisionDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
regulation of cellular response to stressDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
organelle disassemblyDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
regulation of TORC1 signalingDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityCyclin-T1Homo sapiens (human)
transcription by RNA polymerase IICyclin-T1Homo sapiens (human)
response to xenobiotic stimulusCyclin-T1Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-T1Homo sapiens (human)
positive regulation by host of viral transcriptionCyclin-T1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-T1Homo sapiens (human)
cell divisionCyclin-T1Homo sapiens (human)
regulation of transcription by RNA polymerase IICyclin-T1Homo sapiens (human)
positive regulation of DNA-templated transcription, elongationCyclin-T1Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
negative regulation of autophagyEukaryotic translation initiation factor 4EHomo sapiens (human)
G1/S transition of mitotic cell cycleEukaryotic translation initiation factor 4EHomo sapiens (human)
behavioral fear responseEukaryotic translation initiation factor 4EHomo sapiens (human)
mRNA export from nucleusEukaryotic translation initiation factor 4EHomo sapiens (human)
translational initiationEukaryotic translation initiation factor 4EHomo sapiens (human)
regulation of translationEukaryotic translation initiation factor 4EHomo sapiens (human)
negative regulation of translationEukaryotic translation initiation factor 4EHomo sapiens (human)
stem cell population maintenanceEukaryotic translation initiation factor 4EHomo sapiens (human)
neuron differentiationEukaryotic translation initiation factor 4EHomo sapiens (human)
negative regulation of neuron differentiationEukaryotic translation initiation factor 4EHomo sapiens (human)
positive regulation of mitotic cell cycleEukaryotic translation initiation factor 4EHomo sapiens (human)
cellular response to dexamethasone stimulusEukaryotic translation initiation factor 4EHomo sapiens (human)
regulation of translation at postsynapse, modulating synaptic transmissionEukaryotic translation initiation factor 4EHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
positive regulation of cytokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of cell population proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of chemokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of stress-activated MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of osteoblast proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cellular response to amino acid starvationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to interferon-alphaInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of apoptotic processInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of viral genome replicationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein autophosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
defense response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
antiviral innate immune responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of NLRP3 inflammasome complex assemblyInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic progenitor cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eiF2alpha phosphorylation in response to endoplasmic reticulum stressInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-A2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-A2Homo sapiens (human)
regulation of DNA replicationCyclin-A2Homo sapiens (human)
DNA-templated transcriptionCyclin-A2Homo sapiens (human)
Ras protein signal transductionCyclin-A2Homo sapiens (human)
animal organ regenerationCyclin-A2Homo sapiens (human)
response to glucagonCyclin-A2Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusCyclin-A2Homo sapiens (human)
post-translational protein modificationCyclin-A2Homo sapiens (human)
cellular response to leptin stimulusCyclin-A2Homo sapiens (human)
cell cycle G1/S phase transitionCyclin-A2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-A2Homo sapiens (human)
positive regulation of fibroblast proliferationCyclin-A2Homo sapiens (human)
cell divisionCyclin-A2Homo sapiens (human)
cellular response to cocaineCyclin-A2Homo sapiens (human)
cellular response to luteinizing hormone stimulusCyclin-A2Homo sapiens (human)
cellular response to estradiol stimulusCyclin-A2Homo sapiens (human)
cellular response to hypoxiaCyclin-A2Homo sapiens (human)
cellular response to nitric oxideCyclin-A2Homo sapiens (human)
cochlea developmentCyclin-A2Homo sapiens (human)
cellular response to insulin-like growth factor stimulusCyclin-A2Homo sapiens (human)
positive regulation of DNA biosynthetic processCyclin-A2Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityCyclin-A2Homo sapiens (human)
mitotic cell cycle phase transitionCyclin-A2Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
microtubule nucleationCasein kinase I isoform deltaHomo sapiens (human)
Golgi organizationCasein kinase I isoform deltaHomo sapiens (human)
protein localization to Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
protein localization to ciliumCasein kinase I isoform deltaHomo sapiens (human)
protein localization to centrosomeCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform deltaHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform deltaHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform deltaHomo sapiens (human)
COPII vesicle coatingCasein kinase I isoform deltaHomo sapiens (human)
spindle assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
midbrain dopaminergic neuron differentiationCasein kinase I isoform deltaHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
signal transductionCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
endocytosisCasein kinase I isoform deltaHomo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 9Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 9Homo sapiens (human)
DNA repairCyclin-dependent kinase 9Homo sapiens (human)
regulation of DNA repairCyclin-dependent kinase 9Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
transcription initiation at RNA polymerase II promoterCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
cell population proliferationCyclin-dependent kinase 9Homo sapiens (human)
replication fork processingCyclin-dependent kinase 9Homo sapiens (human)
regulation of mRNA 3'-end processingCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
positive regulation by host of viral transcriptionCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
regulation of muscle cell differentiationCyclin-dependent kinase 9Homo sapiens (human)
nucleus localizationCyclin-dependent kinase 9Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 9Homo sapiens (human)
cellular response to cytokine stimulusCyclin-dependent kinase 9Homo sapiens (human)
negative regulation of protein localization to chromatinCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of protein localization to chromatinCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation-coupled chromatin remodelingCyclin-dependent kinase 9Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 9Homo sapiens (human)
male meiosis ICyclin-A1Homo sapiens (human)
spermatogenesisCyclin-A1Homo sapiens (human)
cell divisionCyclin-A1Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityCyclin-A1Homo sapiens (human)
mitotic cell cycle phase transitionCyclin-A1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
exocytosisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase BRSK2Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
neuron differentiationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ERAD pathwaySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of ATP-dependent activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusSerine/threonine-protein kinase BRSK2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase BRSK2Homo sapiens (human)
microtubule cytoskeleton organization involved in establishment of planar polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of retrograde protein transport, ER to cytosolSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of synaptic vesicle clusteringSerine/threonine-protein kinase BRSK2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cell surface receptor signaling pathwayMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
hemopoiesisMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to arsenic-containing substanceMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (71)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
calcium channel regulator activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Sgk1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Sgk1Homo sapiens (human)
potassium channel regulator activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
sodium channel regulator activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
chloride channel regulator activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Sgk1Homo sapiens (human)
magnesium ion bindingDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
transcription cis-regulatory region bindingCyclin-T1Homo sapiens (human)
DNA bindingCyclin-T1Homo sapiens (human)
chromatin bindingCyclin-T1Homo sapiens (human)
protein bindingCyclin-T1Homo sapiens (human)
protein kinase bindingCyclin-T1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activityCyclin-T1Homo sapiens (human)
RNA polymerase bindingCyclin-T1Homo sapiens (human)
7SK snRNA bindingCyclin-T1Homo sapiens (human)
DNA-binding transcription factor bindingCyclin-T1Homo sapiens (human)
molecular condensate scaffold activityCyclin-T1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)
RNA cap bindingEukaryotic translation initiation factor 4EHomo sapiens (human)
RNA 7-methylguanosine cap bindingEukaryotic translation initiation factor 4EHomo sapiens (human)
RNA bindingEukaryotic translation initiation factor 4EHomo sapiens (human)
translation initiation factor activityEukaryotic translation initiation factor 4EHomo sapiens (human)
protein bindingEukaryotic translation initiation factor 4EHomo sapiens (human)
enzyme bindingEukaryotic translation initiation factor 4EHomo sapiens (human)
eukaryotic initiation factor 4G bindingEukaryotic translation initiation factor 4EHomo sapiens (human)
mRNA cap bindingEukaryotic translation initiation factor 4EHomo sapiens (human)
DNA-binding transcription factor bindingEukaryotic translation initiation factor 4EHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
double-stranded RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ATP bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphatase regulator activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
identical protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein bindingCyclin-A2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityCyclin-A2Homo sapiens (human)
protein kinase bindingCyclin-A2Homo sapiens (human)
protein domain specific bindingCyclin-A2Homo sapiens (human)
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein bindingCasein kinase I isoform deltaHomo sapiens (human)
ATP bindingCasein kinase I isoform deltaHomo sapiens (human)
cadherin bindingCasein kinase I isoform deltaHomo sapiens (human)
tau-protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCyclin-dependent kinase 9Homo sapiens (human)
transcription coactivator bindingCyclin-dependent kinase 9Homo sapiens (human)
DNA bindingCyclin-dependent kinase 9Homo sapiens (human)
chromatin bindingCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation factor activityCyclin-dependent kinase 9Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein bindingCyclin-dependent kinase 9Homo sapiens (human)
ATP bindingCyclin-dependent kinase 9Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 9Homo sapiens (human)
kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 9Homo sapiens (human)
7SK snRNA bindingCyclin-dependent kinase 9Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein bindingCyclin-A1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityCyclin-A1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase regulator activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (67)

Processvia Protein(s)Taxonomy
nucleoplasmSerine/threonine-protein kinase Sgk1Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase Sgk1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase Sgk1Homo sapiens (human)
cytosolSerine/threonine-protein kinase Sgk1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase Sgk1Homo sapiens (human)
nuclear speckSerine/threonine-protein kinase Sgk1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Sgk1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Sgk1Homo sapiens (human)
pericentriolar materialDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
cytosolDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
cytoplasmic stress granuleDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
nuclear speckDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
intracellular membrane-bounded organelleDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
cytoskeletonDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 3Homo sapiens (human)
nucleolusCyclin-T1Homo sapiens (human)
nucleusCyclin-T1Homo sapiens (human)
nucleusCyclin-T1Homo sapiens (human)
nucleoplasmCyclin-T1Homo sapiens (human)
cytosolCyclin-T1Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-T1Homo sapiens (human)
P-TEFb complexCyclin-T1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytosolProto-oncogene tyrosine-protein kinase LCK Mus musculus (house mouse)
P-bodyEukaryotic translation initiation factor 4EHomo sapiens (human)
nucleusEukaryotic translation initiation factor 4EHomo sapiens (human)
cytoplasmEukaryotic translation initiation factor 4EHomo sapiens (human)
cytosolEukaryotic translation initiation factor 4EHomo sapiens (human)
cytoplasmic stress granuleEukaryotic translation initiation factor 4EHomo sapiens (human)
eukaryotic translation initiation factor 4F complexEukaryotic translation initiation factor 4EHomo sapiens (human)
nuclear speckEukaryotic translation initiation factor 4EHomo sapiens (human)
chromatoid bodyEukaryotic translation initiation factor 4EHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleEukaryotic translation initiation factor 4EHomo sapiens (human)
perinuclear region of cytoplasmEukaryotic translation initiation factor 4EHomo sapiens (human)
extracellular exosomeEukaryotic translation initiation factor 4EHomo sapiens (human)
postsynapseEukaryotic translation initiation factor 4EHomo sapiens (human)
glutamatergic synapseEukaryotic translation initiation factor 4EHomo sapiens (human)
RISC complexEukaryotic translation initiation factor 4EHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytosolInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ribosomeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
membraneInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
perinuclear region of cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
female pronucleusCyclin-A2Homo sapiens (human)
male pronucleusCyclin-A2Homo sapiens (human)
nucleusCyclin-A2Homo sapiens (human)
nucleoplasmCyclin-A2Homo sapiens (human)
cytoplasmCyclin-A2Homo sapiens (human)
cytosolCyclin-A2Homo sapiens (human)
cyclin A2-CDK1 complexCyclin-A2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-A2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-A2Homo sapiens (human)
nucleusCyclin-A2Homo sapiens (human)
centrosomeCyclin-A2Homo sapiens (human)
cytoplasmCyclin-A2Homo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
nucleoplasmCasein kinase I isoform deltaHomo sapiens (human)
Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
centrosomeCasein kinase I isoform deltaHomo sapiens (human)
spindleCasein kinase I isoform deltaHomo sapiens (human)
cytosolCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
plasma membraneCasein kinase I isoform deltaHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneCasein kinase I isoform deltaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform deltaHomo sapiens (human)
perinuclear region of cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
nucleusCyclin-dependent kinase 9Homo sapiens (human)
nucleusCyclin-dependent kinase 9Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 9Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 9Homo sapiens (human)
membraneCyclin-dependent kinase 9Homo sapiens (human)
PML bodyCyclin-dependent kinase 9Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation factor complexCyclin-dependent kinase 9Homo sapiens (human)
P-TEFb complexCyclin-dependent kinase 9Homo sapiens (human)
nucleoplasmCyclin-A1Homo sapiens (human)
cytosolCyclin-A1Homo sapiens (human)
microtubule cytoskeletonCyclin-A1Homo sapiens (human)
cyclin A1-CDK1 complexCyclin-A1Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-A1Homo sapiens (human)
centrosomeCyclin-A1Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-A1Homo sapiens (human)
cytoplasmCyclin-A1Homo sapiens (human)
nucleusCyclin-A1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
distal axonSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytosolMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nuclear bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
PML bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (651)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347021Human MAP kinase interacting serine/threonine kinase 1 (MKN subfamily)2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.
AID1345722Human MAP kinase interacting serine/threonine kinase 2 (MKN subfamily)2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.
AID720233Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720412Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720425Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720280Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435370Percentage p38beta MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720306Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436076Percentage DYRK1A activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435315Percentage MARK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720150Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435613Percentage MNK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435454Percentage CaMKKalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1375380Inhibition of human MEK1 (M1 to V393 residues) expressed in mammalian expression system at 1 uM by KINOMEscan assay relative to control2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
AID720143Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720065Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1255411Cytotoxicity against human MV4-11 cells assessed as growth inhibition at 72 hrs by resazurin assay2015European journal of medicinal chemistry, Oct-20, Volume: 103An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
AID720371Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1255414Inhibition of Mnk1a (unknown origin) using TAMRA-labeled eIF4E peptide as substrate incubated for 10 mins followed by addition of ATP measured after 90 mins by IMAP TR-FRET analysis2015European journal of medicinal chemistry, Oct-20, Volume: 103An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
AID1399566Inhibition of MNK1 (unknown origin) using S3 as substrate measured after 60 mins by HTRF assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
AID720044Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436072Percentage CK1delta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720032Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435373Percentage PKCzeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720041Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720229Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720385Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720215Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720281Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720466Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720128Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720468Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720382Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720293Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720189Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720058Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720059Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435228Percentage ERK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720136Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720085Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720090Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720108Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720027Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1907987Inhibition of human recombinant full length GST-tagged MNK2 expressed in insect cells using S6 peptide as substrate in presence of [gamma-33P]-ATP incubated for 60 mins by by radiometric scintillation counting method2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor.
AID720037Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720288Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720024Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720251Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436083Percentage ERK8 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720063Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720242Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435363Percentage MELK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720448Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769095Induction of apoptosis in human MOLM-13 cells assessed as early apoptotic cells at 20 uM incubated for 12 hrs by annexin-V and propidium iodide staining based flow cytometry analysis (Rvb = 5.40%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720183Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720205Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201687Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation at G1 phase at 10 uM after 24 hrs by FITC propidium iodide staining based flow cytometry (Rvb = 58.1%)2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720202Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720273Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720480Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435300Percentage PAK6 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720378Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720414Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720228Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720423Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720221Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1544518Antiproliferative activity against human 786-O cells assessed as cell viability at 1 uM incubated for 24 hrs by MTT assay relative to control2019Bioorganic & medicinal chemistry, 06-01, Volume: 27, Issue:11
Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
AID720239Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720129Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720102Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720484Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720329Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720096Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720040Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720471Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436071Percentage CHK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720028Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1399568Antiproliferative activity against human THP1 cells after 96 hrs by MTT assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
AID1769064Inhibition of MNK1/MNK2 in human MOLM-13 cells assessed as reduction in eIF4E phosphorylation at 20 to 40 uM incubated for 12 hrs by western blot analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID435756Percentage Src activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720420Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720307Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1255412Cytotoxicity against human MOLM13 cells assessed as growth inhibition at 72 hrs by resazurin assay2015European journal of medicinal chemistry, Oct-20, Volume: 103An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
AID720324Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435206Inhibition of Aurora B in the presence of 20uM ATP2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720134Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720442Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1544516Inhibition of human MNK1 using CREBtide substrate by gamma-[32P]-ATP competitive inhibition assay2019Bioorganic & medicinal chemistry, 06-01, Volume: 27, Issue:11
Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
AID720093Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720220Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720255Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435335Inhibition of DYRK3 in the presence of 5uM ATP2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720230Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435820Percentage PKCalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720047Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201693Inhibition of Mnk1 in human MV4-11 cells assessed as reduction in eIF4E Ser209 phosphorylation at 10 uM after 24 hrs by Western blotting method2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID435979Percentage MST2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720210Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720317Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435350Percentage ERK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720072Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720034Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1255409Inhibition of CDK2/cyclinA (unknown origin) using TAMRA-labeled eIF4E peptide as substrate incubated for 10 mins followed by addition of ATP measured after 90 mins by IMAP TR-FRET analysis2015European journal of medicinal chemistry, Oct-20, Volume: 103An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
AID435539Percentage PHK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720018Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720417Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720118Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720483Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720071Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201690Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by FITC propidium iodide staining based flow cytometry (Rvb = 17.5%)2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720053Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1534878Inhibition of MNK2 (unknown origin) expressed in HEK293 cells assessed as decrease in eIF4E phosphorylation at Ser209 residues by Western blot analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Targeting the immunity protein kinases for immuno-oncology.
AID720373Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720133Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720238Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720187Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720153Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769037Inhibition of MKN1 (unknown origin) in presence of ATP by HTRF assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID1769068Downregulation of c-myc levels in human MOLM-13 cells at 20 to 40 uM incubated for 12 hrs by western blot analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720370Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720161Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720285Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720304Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1255415Inhibition of human Mnk2a assessed as remaining enzyme activity using TAMRA-labeled eIF4E peptide as substrate at 1 uM incubated for 10 mins followed by addition of ATP measured after 90 mins by IMAP TR-FRET analysis2015European journal of medicinal chemistry, Oct-20, Volume: 103An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
AID435256Percentage p38-gamma MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1399567Inhibition of MNK2 (unknown origin) using S3 as substrate measured after 60 mins by HTRF assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
AID720351Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720430Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID509584Inhibition of MNK22010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.
AID720427Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1399560Antiproliferative activity against human MOLM13 cells after 96 hrs by MTT assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
AID1846619Inhibition of MNK1 in HEK293 cells2021European journal of medicinal chemistry, Jul-05, Volume: 219Progress in developing MNK inhibitors.
AID720364Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720209Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435987Percentage PRK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720026Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720243Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720398Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720321Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720405Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720030Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720113Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID509582Inhibition of MNK12010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.
AID720141Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720340Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720437Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720056Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435681Percentage MAPKAPK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720035Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720155Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720289Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720262Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720094Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720415Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720424Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720464Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720185Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720395Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769093Induction of apoptosis in human MOLM-13 cells assessed as late apoptotic cells at 20 uM incubated for 12 hrs by annexin-V and propidium iodide staining based flow cytometry analysis (Rvb = 3.03%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720105Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720122Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720168Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720411Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1375366Inhibition of MEK (unknown origin) at 1 uM by KINOMEscan assay relative to control2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
AID720154Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720157Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720299Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720083Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435837Inhibition of MNK1 in the presence of 50uM ATP2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720213Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720346Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720223Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720460Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720149Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720036Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720328Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720444Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435123Percentage NEK7 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720356Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720100Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720263Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720274Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720369Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201709Induction of apoptosis in human MV4-11 cells assessed as late apoptotic cells level at 10 uM after 24 hrs by FITC annexin-V/PI staining based flow cytometry (Rvb = 5.4%)2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720440Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720459Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720450Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720138Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720022Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720186Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720290Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720408Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769098Induction of apoptosis in human MOLM-13 cells assessed as live cells at 40 uM incubated for 12 hrs by annexin-V and propidium iodide staining based flow cytometry analysis (Rvb = 91.49%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID435867Percentage NEK2a activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1544517Antiproliferative activity against human SUNE1 cells assessed as cell viability at 1 uM incubated for 24 hrs by MTT assay relative to control2019Bioorganic & medicinal chemistry, 06-01, Volume: 27, Issue:11
Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
AID1201675Induction of apoptosis in human MV4-11 cells at 10 uM after 24 hrs by FITC annexin-V/PI staining based flow cytometry2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720333Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720121Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769058Antiproliferative activity against human K562 cells assessed as reduction of cell viability incubated for 72 hrs by trypan blue staining based cell counting analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID1846621Inhibition of MNK1 (unknown origin) using eIF4E as a substrate in presence of ATP2021European journal of medicinal chemistry, Jul-05, Volume: 219Progress in developing MNK inhibitors.
AID720257Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720277Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720418Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1255413Inhibition of human Mnk2a using TAMRA-labeled eIF4E peptide as substrate incubated for 10 mins followed by addition of ATP measured after 45 mins by ADP-Glo kinase assay2015European journal of medicinal chemistry, Oct-20, Volume: 103An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
AID435881Percentage ROCK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720079Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720379Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720278Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720275Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435704Percentage Aurora B activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720064Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720075Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720438Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720363Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720452Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720240Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720086Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435706Percentage BRSK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435713Percentage CHK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720045Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720348Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720039Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720146Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435213Inhibition of SGK1 in the presence of 20uM ATP2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720227Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435378Percentage S6K1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720349Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720204Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720399Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720021Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720235Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435418Percentage PAK5 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720076Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435493Percentage PKD1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720316Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435819Percentage PKBbeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720246Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720019Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1534877Inhibition of MNK1 (unknown origin) expressed in HEK293 cells assessed as decrease in eIF4E phosphorylation at Ser209 residues by Western blot analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Targeting the immunity protein kinases for immuno-oncology.
AID720043Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435738Percentage p38delta MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720244Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720456Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720188Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720217Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720023Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720066Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720308Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720396Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720292Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769062Inhibition of PIM in human MOLM-13 cells assessed as reduction in phosphorylated 4EBP1 at 20 to 40 uM incubated for 12 hrs by western blot analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720115Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720145Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720325Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720445Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769067Induction of cell cycle arrest in human MOLM-13 cells assessed as G1 phase at 20 uM incubated for 12 hr by propidium iodide based flow cytometry analysis (Rvb= 51.29%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720291Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720469Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201708Induction of apoptosis in human MV4-11 cells assessed as early apoptotic cells level at 10 uM after 24 hrs by FITC annexin-V/PI staining based flow cytometry (Rvb = 3.02%)2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720354Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435223Percentage CSK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1881762Inhibition of human His6-tagged Mnk1 expressed in Escherichia coli assessed as phosphorylation of eukaryotic translation initiation factor 4E2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Update on the Development of MNK Inhibitors as Therapeutic Agents.
AID720082Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720256Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720429Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720147Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435847Percentage DYRK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435260Percentage RSK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1846620Inhibition of eIF4E phosphorylation in HEK293 cells incubated for 60 mins by Western blot assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Progress in developing MNK inhibitors.
AID1375381Inhibition of human MEK2 (M1 to V400 residues) expressed in mammalian expression system at 1 uM by KINOMEscan assay relative to control2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
AID435814Percentage PIM3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720236Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436086Percentage HIPK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720127Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435747Percentage PRAK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720195Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720457Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720313Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720389Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720106Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720173Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720119Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720184Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720208Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720335Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720057Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720374Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720327Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720174Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720074Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720384Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720162Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720341Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720375Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720194Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720160Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201706Reduction in cyclin D1 expression in human MV4-11 cells at 10 uM after 24 hrs by Western blotting method2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720104Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720110Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720038Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720472Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720031Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720165Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769040Antiproliferative activity against human MOLM13 cells assessed as reduction of cell viability incubated for 72 hrs by trypan blue staining based cell counting analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720084Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720193Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720446Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720474Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720260Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720298Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769071Downregulation of cyclin-D1 levels in human MOLM-13 cells at 20 to 40 uM incubated for 12 hrs by western blot analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720099Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720179Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201660Inhibition of Mnk1 (unknown origin) pre-incubated for 10 mins before eIF4E peptide substrate addition by ADP-Glo kinase assay2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720048Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720482Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720305Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720377Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720234Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720400Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1375378Inhibition of human ABL1 E255K mutant (S229 to K512 residues) expressed in mammalian expression system at 1 uM by KINOMEscan assay relative to control2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
AID720416Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720264Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720314Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720344Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720207Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720342Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720178Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720140Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720114Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720125Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720310Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435723Percentage GSK3-beta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720224Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720069Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720473Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720302Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720336Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720196Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720060Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769083Induction of cell cycle arrest in human MOLM-13 cells assessed as G1 phase at 40 uM incubated for 12 hr by propidium iodide based flow cytometry analysis (Rvb= 51.29%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720355Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720098Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720319Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720172Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720332Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720137Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720073Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720116Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720279Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720409Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720200Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720132Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435854Percentage IKK-beta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720272Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720347Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720070Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435995Percentage SRPK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1201689Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation at S phase at 10 uM after 24 hrs by FITC propidium iodide staining based flow cytometry (Rvb = 16.7%)2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720218Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436036Percentage Lck activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720361Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720190Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435233Percentage HIPK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1201688Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation at subG1 phase at 10 uM after 24 hrs by FITC propidium iodide staining based flow cytometry (Rvb = 7.7%)2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720049Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435338Percentage CaMK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1375361Inhibition of wild-type human partial length MNK2 (G63 to S388 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
AID720163Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720055Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720478Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720428Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720380Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720181Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720097Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720214Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720376Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720269Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720296Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769082Induction of cell cycle arrest in human MOLM-13 cells assessed as sub-G1 phase at 40 uM incubated for 12 hr by propidium iodide based flow cytometry analysis (Rvb= 4.78%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720212Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720394Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720144Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436061Inhibition of BRSK2 in the presence of 50uM ATP2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720248Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769092Induction of apoptosis in human MOLM-13 cells assessed as necrotic cells at 20 uM incubated for 12 hrs by annexin-V and propidium iodide staining based flow cytometry analysis (Rvb = 0.06%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720167Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720042Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769038Inhibition of MKN2 (unknown origin) in presence of ATP by HTRF assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720046Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720387Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720267Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720426Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769097Induction of apoptosis in human MOLM-13 cells assessed as late apoptotic cells at 40 uM incubated for 12 hrs by annexin-V and propidium iodide staining based flow cytometry analysis (Rvb = 3.03%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720211Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720454Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720117Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435215Percentage AMPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720247Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201678Induction of caspase-3/7 activation in human MV4-11 cells at 10 uM after 24 hrs2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720158Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID606664Inhibition of human recombinant PKR autophosphorylation using poly[I:C] after 10 mins by luminescent assay2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Identification of new inhibitors of protein kinase R guided by statistical modeling.
AID720052Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720443Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720282Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720111Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720367Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720101Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720447Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720087Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720432Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720092Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720311Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720107Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720201Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720067Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720180Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435427Percentage PKBalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720112Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720436Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769057Antiproliferative activity against human HL-60 cells assessed as reduction of cell viability incubated for 72 hrs by trypan blue staining based cell counting analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720249Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769096Induction of apoptosis in human MOLM-13 cells assessed as necrotic cells at 40 uM incubated for 12 hrs by annexin-V and propidium iodide staining based flow cytometry analysis (Rvb = 0.06%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID435238Percentage JNK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720309Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720449Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720142Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720312Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720479Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720337Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435621Percentage p38alpha MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720461Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720401Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720080Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1846622Inhibition of MNK2 (unknown origin) using eIF4E as a substrate in presence of ATP2021European journal of medicinal chemistry, Jul-05, Volume: 219Progress in developing MNK inhibitors.
AID1769094Induction of apoptosis in human MOLM-13 cells assessed as live cells at 20 uM incubated for 12 hrs by annexin-V and propidium iodide staining based flow cytometry analysis (Rvb = 91.49%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720061Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720077Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1881763Inhibition of human His6-tagged Mnk2 expressed in Escherichia coli assessed as phosphorylation of eukaryotic translation initiation factor 4E2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Update on the Development of MNK Inhibitors as Therapeutic Agents.
AID435375Percentage RSK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720343Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720182Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720283Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769069Downregulation of mcl-1 levels in human MOLM-13 cells at 20 to 40 uM incubated for 12 hrs by western blot analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID435461Percentage CK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720388Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720360Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720029Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720407Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720203Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435865Percentage MKK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720413Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720241Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720357Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720259Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720068Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201710Induction of apoptosis in human MV4-11 cells assessed as necrotic cells level at 10 uM after 24 hrs by FITC annexin-V/PI staining based flow cytometry (Rvb = 0.1%)2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720033Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720433Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769077Induction of cell cycle arrest in human MOLM-13 cells assessed as sub-G1 phase at 20 uM incubated for 12 hr by propidium iodide based flow cytometry analysis (Rvb= 4.78%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720404Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720216Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720276Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720467Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720419Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720322Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720406Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720458Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720294Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720131Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720455Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435450Inhibition of CK1delta in the presence of 20uM ATP2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720315Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435339Percentage CaMKKbeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720206Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720151Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720402Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720463Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720109Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID436037Percentage MAPKAPK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720266Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201707Induction of apoptosis in human MV4-11 cells assessed as viable cells level at 10 uM after 24 hrs by FITC annexin-V/PI staining based flow cytometry (Rvb = 91.49%)2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720303Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720078Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720169Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720422Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720054Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720368Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720191Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720386Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435728Percentage JNK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435317Percentage PIM1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435727Percentage JNK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720362Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435718Percentage EF2K activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720431Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720139Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720197Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720258Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720268Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720265Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201662Growth inhibition of human MV4-11 cells after 72 hrs by resazurin assay2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720470Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435417Percentage PAK4 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720462Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720081Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720192Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720199Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720295Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720334Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720350Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720372Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201705Induction of apoptosis in human MV4-11 cells assessed as induction of PARP cleavage expression at 10 uM after 24 hrs by Western blotting method2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720171Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720393Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720156Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1201704Induction of apoptosis in human MV4-11 cells assessed as reduction in Mcl1 expression at 10 uM after 24 hrs by Western blotting method2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720477Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720175Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720253Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769099Induction of apoptosis in human MOLM-13 cells assessed as early apoptotic cells at 40 uM incubated for 12 hrs by annexin-V and propidium iodide staining based flow cytometry analysis (Rvb = 5.40%)2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720476Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720164Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720177Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720091Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720365Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720284Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720403Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435225Percentage DYRK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720434Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720252Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720475Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720330Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435883Percentage SGK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720383Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720089Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1399572Inhibition of MNK2 (unknown origin)2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
AID720051Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720323Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720095Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720353Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720226Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720397Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1255416Selectivity ratio of IC50 for human Mnk2 to IC50 for human Mnk12015European journal of medicinal chemistry, Oct-20, Volume: 103An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
AID720271Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720441Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720120Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720198Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435669Percentage PDK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720439Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720062Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435501Percentage SmMLCK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720481Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720123Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435731Percentage MNK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1201661Inhibition of Mnk2 (unknown origin) pre-incubated for 10 mins before eIF4E peptide substrate addition by ADP-Glo kinase assay2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
AID720453Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720126Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720381Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1769039Inhibition of MKN1 (unknown origin) at 1 uM in presence of ATP by HTRF assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID1255410Inhibition of CDK9/cyclinT1 (unknown origin) using TAMRA-labeled eIF4E peptide as substrate incubated for 10 mins followed by addition of ATP measured after 90 mins by IMAP TR-FRET analysis2015European journal of medicinal chemistry, Oct-20, Volume: 103An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
AID720017Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435949Inhibition of Lck in the presence of 50uM ATP2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720219Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720390Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720318Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720338Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720451Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435374Percentage PLK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435734Percentage NEK6 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720270Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720358Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720345Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720124Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435176Percentage PIM2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720301Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720254Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720326Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720166Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435541Percentage PKA activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720159Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720287Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720465Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720152Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720245Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720331Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720297Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720250Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435962Percentage CDK2-cyclinA activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720050Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720435Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720020Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1375379Inhibition of human ABL1 (S229 to K512 residues) expressed in mammalian expression system at 1 uM by KINOMEscan assay relative to control2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
AID720232Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720225Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435576Inhibition of MNK2 in the presence of 50uM ATP2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1769063Inhibition of PIM in human MOLM-13 cells assessed as reduction of BAD phosphorylation at 20 to 40 uM incubated for 12 hrs by western blot analysis2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Optimization of 4,6-Disubstituted Pyrido[3,2-
AID720391Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720339Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720088Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1375382Inhibition of human RET (E713 to D1014 residues) expressed in bacterial expression system at 1 uM by KINOMEscan assay relative to control2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
AID720286Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435842Percentage Aurora C activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720261Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720176Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720025Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720130Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720421Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720320Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1255408Inhibition of human Mnk2a using TAMRA-labeled eIF4E peptide as substrate incubated for 10 mins followed by addition of ATP measured after 90 mins by IMAP TR-FRET analysis2015European journal of medicinal chemistry, Oct-20, Volume: 103An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
AID720392Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720359Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1907986Inhibition of human recombinant full length GST-tagged MNK1 expressed in baculovirus expression system using S6 peptide as substrate in presence of [gamma-33P]-ATP incubated for 60 mins by radiometric scintillation counting method2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor.
AID720231Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720300Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID435250Percentage MSK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID720103Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720410Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720222Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720237Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720135Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1399569Antiproliferative activity against human HCT116 cells after 96 hrs by MTT assay2018Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
AID720352Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720170Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID509610Inhibition of SGK12010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.
AID720148Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720366Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (23.44)29.6817
2010's36 (56.25)24.3611
2020's13 (20.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.78 (24.57)
Research Supply Index4.17 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (4.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other61 (95.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]